Acute haemorrhagic ulcerative colitis is a severe form of inflammatory bowel disease that can lead to life-threatening complications requiring urgent medical care. Understanding how this condition is managed through various treatment approaches, from intensive medical therapies to surgical interventions, can help patients and families navigate this challenging medical emergency.
Managing a Medical Emergency: Treatment Goals in Acute Severe Ulcerative Colitis
When ulcerative colitis suddenly becomes severe and life-threatening, doctors face a medical emergency that requires immediate hospitalization and intensive care. This form of the disease, which causes dangerous bleeding and widespread ulceration throughout the colon, demands prompt action to prevent potentially fatal complications such as colon perforation, severe dehydration, or uncontrolled bleeding from the rectum.[1][2]
The main goals of treating acute severe ulcerative colitis are to quickly bring inflammation under control, prevent dangerous complications, and ultimately restore the patient to a state where symptoms are manageable. Treatment decisions depend on how quickly the patient responds to initial therapies, the extent of colon damage, and whether complications have already developed. Medical teams work against the clock because delays in treatment can lead to worsening outcomes.[8][9]
Healthcare professionals use a multidisciplinary approach involving gastroenterologists, colorectal surgeons, nurses, and nutritionists. This team-based care ensures that if medical treatments fail to work within a specific timeframe, surgical options can be quickly implemented. The mortality rate for acute severe ulcerative colitis has dramatically improved over the decades, dropping from 30 to 60 percent in the pre-steroid era to less than 1 percent in specialist centers today, thanks to better understanding of treatment timing and options.[8][9]
Standard Treatment Approaches for Acute Severe Episodes
The cornerstone of initial treatment for acute severe ulcerative colitis is intravenous corticosteroids, which are powerful anti-inflammatory medications given directly into the bloodstream. These steroids work by suppressing the overactive immune response that causes inflammation and damage to the colon lining. The medicine is delivered continuously through a drip in the arm, allowing doctors to ensure the patient receives the full dose even when they cannot eat or drink normally.[8][9][13]
Patients receiving intravenous steroids are monitored closely in hospital. Healthcare providers assess response to treatment by day three of admission, which is a critical decision point. If the patient shows improvement with reduced stool frequency, less bleeding, and better overall condition, the steroid treatment continues. However, if there is no improvement or only partial improvement by day three, doctors must consider alternative therapies because continuing steroids alone is unlikely to prevent complications.[8][9]
Alongside corticosteroids, patients receive several supportive treatments. Venous thromboembolism prophylaxis, or blood clot prevention therapy, is crucial because severe inflammation increases the risk of dangerous blood clots forming in the legs or lungs. Patients also receive nutritional support, with oral or enteral feeding as tolerated, to maintain strength and support healing. Healthcare teams carefully monitor fluid and electrolyte balance to prevent dehydration, which can result from frequent diarrhea and fluid loss.[9][3]
Infection screening is a vital part of the initial assessment. Doctors test stool samples to rule out infections with bacteria like Clostridium difficile, which can mimic or worsen ulcerative colitis symptoms. If an infection is present, it must be treated before or alongside other therapies because antibiotics alone may not resolve severe colitis, but untreated infection can interfere with recovery.[9]
Common side effects of short-term corticosteroid use include acne, weight gain, increased appetite, mood changes such as irritability, and difficulty sleeping. More serious long-term side effects like bone weakening or cataracts typically occur only with prolonged use, which is why steroids are not used for maintenance therapy in ulcerative colitis. The goal is to use these powerful drugs to control the acute episode, then transition to other medications for long-term management.[13][2]
Rescue Therapies When Steroids Are Not Enough
When patients do not respond adequately to intravenous steroids by day three, medical teams must act quickly to implement rescue therapy. Two main options exist: cyclosporin and infliximab. Both are powerful immunosuppressive treatments that work differently from steroids and can prevent the need for emergency surgery.[8][9]
Cyclosporin is an immunosuppressant medicine that reduces the activity of the immune system, thereby decreasing inflammation. It is given slowly through an intravenous drip at a dose of 2 milligrams per kilogram of body weight per day. Treatment typically continues for around seven days. Research shows that approximately 75 percent of patients have short-term response to cyclosporin, meaning their symptoms improve enough to avoid immediate surgery. About 50 percent maintain long-term response, particularly when they begin taking thiopurine medicines (such as azathioprine) around day seven to help maintain the improvement.[8][13]
Side effects of intravenous cyclosporin can include uncontrollable shaking or trembling of body parts, excessive hair growth, extreme tiredness, swollen gums, nausea, vomiting, and diarrhea. More serious complications can include high blood pressure and reduced kidney and liver function, so patients are monitored regularly with blood tests during treatment to check for these problems.[13]
Infliximab is a type of medicine called a biologic that works by targeting and blocking a protein called tumor necrosis factor. This protein plays a key role in causing inflammation in ulcerative colitis. Infliximab is given as a single intravenous infusion at a dose of 5 milligrams per kilogram of body weight. Like cyclosporin, it has a response rate of approximately 70 percent in the short term and 50 percent for long-term control.[8][13]
Recent clinical trials have shown that cyclosporin and infliximab are equally effective as rescue therapies for acute severe ulcerative colitis. The choice between them often depends on the patient’s previous treatment history, any existing conditions, and the doctor’s experience with each medicine. Patients who do not respond to either cyclosporin or infliximab within seven days should be considered for surgical treatment because further delay increases the risk of life-threatening complications.[8][14]
When Surgery Becomes Necessary
Surgery is sometimes the best treatment option for acute severe ulcerative colitis, either as an emergency procedure for immediate life-threatening complications or as a planned intervention when medical therapies have failed. The most common surgical procedure involves removing the diseased colon through an operation called a colectomy.[9][11]
Immediate surgery is required for patients with intestinal perforation (a hole in the colon), uncontrollable bleeding that causes severe blood loss, or toxic megacolon (a condition where inflammation spreads deep into the intestinal wall and the colon stops working and becomes dangerously dilated). These are life-threatening emergencies that cannot wait for medical treatment to work.[9][3]
For patients who do not have immediate life-threatening complications but fail to respond to both corticosteroids and rescue therapy, planned surgery offers a chance to remove the diseased tissue and restore health. While surgery is a major decision with significant recovery time, it can ultimately improve quality of life for patients with severe disease that does not respond to medical management.[11][13]
Innovative Treatments Being Studied in Clinical Trials
Research into new treatments for severe ulcerative colitis continues to advance, with several promising therapies being tested in clinical trials around the world. These studies aim to find better options for patients who do not respond to standard treatments or who experience significant side effects from current medications.
JAK Inhibitors: A New Class of Medicines
JAK inhibitors represent an innovative class of medicines that work by blocking specific enzymes called Janus kinases inside immune cells. These enzymes play a crucial role in transmitting signals that cause inflammation. By blocking them, JAK inhibitors can reduce inflammation throughout the colon without requiring intravenous infusions like biologic medicines.[13]
The advantage of JAK inhibitors is that they are taken as oral tablets, making them more convenient than infusion therapies. Clinical trials have studied these medicines in moderate to severe ulcerative colitis, including some patients with acute episodes. The trials typically progress through three phases: Phase I studies test safety in small groups of volunteers, Phase II trials assess whether the medicine works effectively in patients with the disease, and Phase III trials compare the new treatment to current standard therapies in larger patient groups.[13]
Biologic Medicines: Targeting Specific Inflammatory Pathways
Beyond infliximab, which is already used in acute severe cases, researchers are testing additional biologic medicines that target different proteins involved in the inflammatory process. These medicines work by blocking receptors or proteins that the immune system uses to trigger inflammation in the intestinal lining. By preventing these signals from being sent or received, biologic medicines can reduce damage to the colon.[13]
Alpha 4 integrin inhibitors are one type of biologic being studied. These medicines prevent certain white blood cells from traveling to the intestines by blocking proteins on their surface that allow them to stick to blood vessel walls. This keeps inflammatory cells out of the colon, reducing inflammation.[13]
Interleukin inhibitors are another category of biologic medicines in clinical trials. Interleukins are chemical messengers that immune cells use to communicate and coordinate inflammatory responses. By blocking specific interleukins involved in ulcerative colitis, these medicines can disrupt the inflammatory cascade before it damages the colon lining.[13]
Clinical trials for biologic medicines typically involve administering the treatment as an intravenous infusion every four to twelve weeks or as an injection every one to two weeks. Researchers measure how many patients achieve remission (no symptoms), how quickly symptoms improve, and whether the colon lining heals. They also carefully monitor for side effects and complications.[13]
Sphingosine 1-Phosphate Receptor Modulators
Sphingosine 1-phosphate receptor modulators are oral medications that work by a different mechanism. They prevent certain types of immune cells called lymphocytes from leaving lymph nodes and traveling to sites of inflammation in the body, including the colon. By keeping these inflammatory cells trapped in lymph nodes, the medicines reduce the immune attack on the intestinal lining.[13]
This class of medicine has shown promise in clinical trials for moderate to severe ulcerative colitis. The advantage is that patients take the medication by mouth rather than requiring injections or infusions. Trials are studying the optimal dosing, timing of treatment, and which patients are most likely to benefit from this approach.
Trial Locations and Patient Eligibility
Clinical trials for ulcerative colitis treatments are conducted worldwide, including locations in the United States, Europe, and other regions. Patients interested in participating in trials typically need to meet specific criteria, such as having moderate to severe disease that has not responded adequately to standard treatments, being within certain age ranges, and not having specific health conditions that would make trial participation unsafe.
Trial eligibility often excludes patients with certain complications, active infections, or those taking medications that might interfere with the study treatment. Doctors conducting trials carefully screen potential participants to ensure they can safely receive the experimental therapy and provide meaningful data to answer research questions.
Preliminary results from many of these trials have shown encouraging signs, including improvements in clinical symptoms, reductions in inflammatory markers in the blood, and healing of the colon lining visible on colonoscopy. However, these treatments are still being studied, and their safety and effectiveness compared to existing therapies need to be fully established before they become widely available.
Most Common Treatment Methods
- Intravenous Corticosteroids
- Administered continuously through a drip in the arm for patients hospitalized with acute severe ulcerative colitis[8][9]
- Work by suppressing the overactive immune response causing colon inflammation
- Response assessed by day three of treatment to determine if alternative therapies are needed
- Short-term side effects include weight gain, mood changes, insomnia, and increased appetite[13]
- Rescue Immunosuppressive Therapy
- Cyclosporin given intravenously at 2 mg/kg per day for approximately seven days[8]
- Achieves short-term response in approximately 75% of patients and long-term response in 50%[8]
- Side effects include tremors, excessive hair growth, fatigue, swollen gums, and potential kidney and liver problems[13]
- Long-term response improved when patients start thiopurine medicines around day seven
- Biologic Medicines
- Infliximab administered as single intravenous infusion at 5 mg/kg body weight[8]
- Targets and blocks tumor necrosis factor protein involved in inflammation
- Approximately 70% short-term and 50% long-term response rates[8]
- Given through hospital infusion every 4 to 12 weeks for maintenance[13]
- Other biologics including alpha 4 integrin inhibitors and interleukin inhibitors being studied in trials[13]
- JAK Inhibitors
- Oral tablet medications that block Janus kinase enzymes in immune cells[13]
- Work by preventing transmission of inflammatory signals inside cells
- Being studied in clinical trials for moderate to severe ulcerative colitis
- Advantage of oral administration rather than injections or infusions
- Supportive Care
- Surgical Treatment
